Clinical Trials List
2023-08-10 - 2026-12-31
Phase I
Recruiting3
ICD-10C78.5
Secondary malignant neoplasm of large intestine and rectum
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9197.5
Secondary malignant neoplasm of large intestine and rectum
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Chia-Jui Yen 無
- Chun-Hui Lee 無
- Chien-Chung Lin 無
- Jui-Hung Tsai 無
- 黃盈慈 無
- 蘇勇曄 無
- Peng-Chan Lin 無
- 顏志傑 無
- Shang-Hung Chen 無
- Po-Wen Lin Division of General Surgery
- Shang-Yin Wu 無
- 黃怡璇 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 梁逸歆 無
- CHAO-CHI HO CHAO-CHI HO 無
- 許嘉林 無
- 吳尚俊 無
- 徐偉勛 無
- James Chih-Hsin Yang 無
- JIN-YUAN SHIH 無
- 蔡子修 無
- 林昭文 Division of Ophthalmology
- 陳國興 無
- Kun-Huei Yeh 無
- 楊景堯 無
- 廖唯昱 無
- 廖斌志 無
- Jih-Hsiang Lee 無
- Chong-Jen Yu 無
- YEN-TING LIN 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
18 participants
-
Global
830 participants
